文献速递白血病淋巴瘤MDS 与骨髓增殖性肿瘤

基于基础血液检查的初级保健血液恶性肿瘤风险分层模型开发与验证

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests.
PubMed 文献 · Br J Haematol · 2026-09-24

该工具可能辅助初级保健风险评价,但不能替代临床评估。

要点

  • CBC-HEMA基于全血细胞计数、年龄、性别和C反应蛋白,可评估6个月至3年血液恶性肿瘤风险。
  • 对慢性淋巴细胞白血病和骨髓增殖性疾病预测优秀,但对非霍奇金淋巴瘤和浆细胞疾病预测不准确。
  • 外部验证在初级保健人群中结果相似,但在健康筛查人群中性能较差。

核心结论

  • CBC-HEMA可用于初级保健中血液恶性肿瘤的总体风险分层,但不能替代临床评估。
  • 该工具对慢性淋巴细胞白血病和骨髓增殖性疾病预测优秀,但对非霍奇金淋巴瘤和浆细胞疾病预测不准确。
  • 在健康人群筛查中性能较差,不适用于筛查健康人群。

主要发现

  • CBC-HEMA预测6个月、1年和3年内任何血液恶性肿瘤的AUC分别为0.81、0.78和0.71。
  • 对慢性淋巴细胞白血病和骨髓增殖性疾病的预测优秀,但对非霍奇金淋巴瘤和浆细胞疾病预测不准确。
  • 在丹麦西部初级保健患者外部验证结果相似,但在英国生物银行背景人群中性能较差。

关键数值与推荐

  • CBC-HEMA使用全血细胞计数、年龄、性别和C反应蛋白测量值进行风险分层。
  • 预测时间范围为6个月、1年和3年内的任何血液恶性肿瘤风险。

临床怎么用

  • CBC-HEMA可能支持初级保健中的风险评价,但cannot replace a clinical evaluation。
  • 不适用于筛查健康人群。

局限性

  • 在健康人群筛查中性能较差,不适用于筛查健康人群。
  • 对非霍奇金淋巴瘤和浆细胞疾病预测不准确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Haematological malignancies are rare in primary care and are hard to predict. Existing prediction models often require a specific working diagnosis and are based on extensive clinical information, access to which may be limited at initial work-up in primary care. We aimed to develop a tool for estimating overall risk of haematological malignancy in primary care patients using simple data inputs. Including all full blood cell counts (FBCs) measured from 2000 to 2016 in 856 403 adult primary care patients in Eastern Denmark, we used machine learning to develop CBC-HEMA, a risk assessment tool using FBCs, age, sex and C-reactive protein measures to stratify 'any haematological malignancy' risk within 6 months, 1 year and 3 years with area under the curve (AUC) of 0.81, 0.78 and 0.71 respectively. Predictions of chronic lymphoid leukaemia and myeloproliferative disease were excellent, while CBC-HEMA was unable to accurately predict non-Hodgkin lymphoma and plasma cell dyscrasia. External validation was conducted in 123 015 primary care patients from Western Denmark with similar results and in 418 410 individuals from the background population cohort UK Biobank with inferior performance showing unfitness in screening healthy populations. The CBC-HEMA https://shiny.sund.ku.dk/CopLab/blood-cancer-risk-prediction/ may support risk assessment in primary care but cannot replace a clinical evaluation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Christensen ME, Sachs MC, Dunn WG, et al. Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests. Br J Haematol. 2026. PMID: 42786643. doi:10.1111/bjh.70798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。